Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Clinical trial NCT03624036 · TERMINATED

Trial details

NCT number

NCT03624036

Sponsor

Kite, A Gilead Company

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2018-11-15

Primary completion

2021-02-12

Enrollment

16

View on ClinicalTrials.gov